Tag: Brodalumab

According to population pharmacokinetic modeling, the effective half-life of Siliq (brodalumab) at steady state is approximately 10.9 to 11.7 days. Understanding what is the half-life of Siliq is crucial for determining its dosing schedule and overall therapeutic efficacy in treating moderate to severe plaque psoriasis.

Originally developed by Amgen, the biologic medication brodalumab underwent several key ownership changes before its market debut, creating a complex manufacturing and commercialization landscape. The answer to who makes brodalumab depends heavily on the geographic region, as different pharmaceutical companies hold marketing rights in different parts of the world.

In phase 3 clinical trials, over 83% of patients taking Siliq (brodalumab) achieved at least 75% clear skin within 12 weeks. This impressive statistic shows **how effective is Siliq** for many individuals with moderate-to-severe plaque psoriasis, but a full understanding requires examining long-term data and side effect profiles.